

CPT® Proprietary Laboratory Analyses (PLA) Codes: Long Descriptors

It is important to note that further CPT Editorial Panel (Panel) or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

Most recent changes to the CPT® Proprietary Laboratory Analyses (PLA) Long Descriptor document:

- Deletion of 10 codes (0033U, 0131U, 0132U, 0135U, 0361U, 0508U, 0509U, 0544U, 0550U, 0551U) and addition of 14 codes (0600U–0613U) accepted by the CPT Editorial Panel.
- Revision of the proprietary name for code 0524U.
- Update long descriptor for code 0365U by removing the comma after “VEGFA”).
- Update long descriptor numeric values for codes 0537U, 0565U, 0569U to include thousand separators.
- Update long descriptor for code 0596U by replacing the term “prototype” with the term “proteotype”.
- Deleted codes in this document appear with a ~~strikethrough~~.

Proprietary laboratory analyses (PLA) codes describe proprietary clinical laboratory analyses and can be either provided by a single (“sole-source”) laboratory or licensed or marketed to multiple providing laboratories (eg, cleared or approved by the Food and Drug Administration [FDA]).

This subsection includes advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs), as defined under the Protecting Access to Medicare Act (PAMA) of 2014. These analyses may include a range of medical laboratory tests including, but not limited to, multianalyte assays with algorithmic analyses (MAAA) and genomic sequencing procedures (GSP). The descriptor nomenclature follows, where possible, existing code conventions (eg, MAAA, GSP).

Unless specifically noted, even though the Proprietary Laboratory Analyses section of the code set is located at the end of the Pathology and Laboratory section of the code set, a PLA code does not fulfill Category I code criteria. PLA codes are not required to fulfill the Category I criteria. The standards for inclusion in the PLA section are:

- The test must be commercially available in the United States for use on human specimens and
- The clinical laboratory or manufacturer that offers the test must request the code.

For similar laboratory analyses that fulfill Category I criteria, see codes listed in the numeric 80000 series.

When a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. The service should not be reported with any other CPT code(s) and other CPT code(s) should not be used to report services that may be reported with that specific PLA code. These codes encompass all analytical services required for the analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection). For molecular analyses, additional procedures that are required prior to cell lysis (eg, microdissection [codes 88380 and 88381]) may be reported separately.

Codes in this subsection are released on a quarterly basis to expedite dissemination for reporting. PLA codes will be published electronically on the AMA CPT website (ama-assn.org/cpt-pla-codes), distributed via CPT data files on a quarterly basis, and, at a minimum, made available in print annually in the CPT codebook. Go to www.ama-assn.org/sites/default/files/media-browser/public/physicians/cpt/cpt-pla-codes-long.pdf for the most current listing. See the Introduction section of the CPT code set for a complete list of the dates of release and implementation.

All codes that are included in this section are also included in Appendix O, with the procedure's proprietary name. In order to report a PLA code, the analysis performed must fulfill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. In some instances, the descriptor language of PLA codes may be identical and the code may only be differentiated by the listed proprietary name in Appendix O. When more than one PLA has an identical descriptor, the codes will be denoted by the symbol "X."

All PLA tests will have assigned codes in the PLA section of the code set. Any PLA coded test(s) that satisfies Category I criteria and has been accepted by the CPT Editorial Panel will be designated by the addition of the symbol "↑↓" to the existing PLA code and will remain in the PLA section of the code set.

If a proprietary test has already been accepted for a Category I code and a code has not been published, subsequent application for a PLA code will take precedence. The code will only be placed in the PLA section.

The accuracy of a PLA code is to be maintained by the original applicant, or the current owner of the test kit or laboratory performing the proprietary test.

A new PLA code is required when:

1. Additional nucleic acid (DNA or RNA) and/or protein analysis(es) are added to the current PLA test, or
2. The name of the PLA test has changed in association with changes in test performance or test characteristics.

The addition or modification of the therapeutic applications of the test require submission of a code change application, but it may not require a new code number.

Proprietary Name and Clinical Laboratory and/or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective Date	Publication
Serotonin Receptor Genotype (<i>HTR2A</i> and <i>HTR2C</i>), Mayo Clinic, Mayo Clinic	0033U	<i>HTR2A</i> (5-hydroxytryptamine receptor 2A), <i>HTR2C</i> (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, <i>HTR2A</i> rs7997012 [c.614-2211T>C], <i>HTR2C</i> rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027
Real-time quaking-induced conversion for prion detection (RT-QulC), National Prion Disease Pathology Surveillance Center	X0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative (For additional PLA code with identical clinical descriptor, see 0584U. See Appendix O or the most current listing on the AMA CPT website to	New Parenthetical Note and Duplicate PLA Test Symbol Released to AMA Website July 1, 2025	New Parenthetical Note and Duplicate PLA Test Symbol Effective October 1, 2025	New Parenthetical Note and Duplicate PLA Test Symbol Added to Publication CPT® 2026

		determine appropriate code assignment)			
Pigmented Lesion Assay (PLADermTech Melanoma Test), DermTech DERM-JES Holdings, LLC d/b/a DermTech, LLC, DERM-JES Holdings, LLC d/b/a DermTech, LLC	0089U	Oncology (melanoma), gene expression profiling by RTqPCR, <i>PRAME</i> and <i>LINC00518</i> , superficial collection using adhesive patch(es)	Revision to Proprietary and Laboratory Name Released to AMA Website April 1, 2025	Revision to Proprietary and Laboratory Name Effective July 1, 2025	Revision to Proprietary and Laboratory Name Publication CPT® 2026
Esophageal String Test™ (EST), Children's Hospital Colorado Department of Pathology and Laboratory Medicine EnteroTrack™ Labs, EnteroTrack, LLC	▲0095U	Eosinophilic esophagitis, 2 protein biomarkers (Eotaxin-3 [<i>CCL26 {C-C motif chemokine ligand 26}</i>] and mMajor bBasic pProtein [<i>PRG2 {proteoglycan 2, pro eosinophil major basic protein}</i>]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis	Revision Released to AMA Website October 1, 2024 Revision to Laboratory, and/or Manufacturer Name Released to AMA Website December 30, 2024	Revision Effective January 1, 2025	Revision Publication CPT® 2026
+RNAinsight™ for BreastNext®, Ambry Genetics	+0131U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) (Use 0131U in conjunction with 81162, 81432, 0102U)	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027
+RNAinsight™ for OvaNext®, Ambry Genetics	+0132U	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027

		addition to code for primary procedure) (Use 0132U in conjunction with 81162, 81432, 0103U)			
+RNAinsight™ for GYNPlus®, Ambry Genetics	+0135U	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) (Use 0135U in conjunction with 81162)	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027
PreciseBreast™ PreciseDx™ Breast Cancer Test, PreciseDx, PreciseDx	0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	Revision to Proprietary Name Released to AMA Website April 1, 2025	Revision to Proprietary Name Effective July 1, 2025	Revision to Proprietary Name Publication CPT® 2026
Xpert® Xpress CoV-2/Flu/RSV plus (SARS-CoV-2 and Flu targets), Cepheid®	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	Deletion Released to AMA Website April 1, 2025	Deletion Effective July 1, 2025	Deletion Publication CPT® 2026
Xpert® Xpress CoV-2/Flu/RSV plus (all targets), Cepheid®	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	Deletion Released to AMA Website April 1, 2025	Deletion Effective July 1, 2025	Deletion Publication CPT® 2026
RadTox™ cfDNA test, DiaCarta Clinical Lab, DiaCarta, Inc	▲0285U	Oncology, <u>disease progression and response monitoring</u> to radiation, chemotherapy, or other <u>systematic cancer treatments</u>, cell-free DNA, quantitative	Revision Released to AMA Website April 1, 2025	Revision Effective July 1, 2025	Revision Publication CPT® 2026

		branched chain DNA amplification, plasma, reported in <u>as ng/mL</u> a radiation toxicity score			
DetermaRx™, Oncoocyte Corporation RiskReveal™, Razor Genomics	0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (<i>BAG1</i> , <i>BRCA1</i> , <i>CDC6</i> , <i>CDK2AP1</i> , <i>ERBB3</i> , <i>FUT3</i> , <i>IL11</i> , <i>LCK</i> , <i>RND3</i> , <i>SH3BGR</i> , <i>WNT3A</i>) and 3 reference genes (<i>ESD</i> , <i>TBP</i> , <i>YAP1</i>), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	Revision to Proprietary, Laboratory, and/or Manufacturer Name Released to AMA Website December 30, 2024	Revision to Proprietary, Laboratory, and/or Manufacturer Name Effective April 1, 2025	Revision to Proprietary, Laboratory, and/or Manufacturer Name Publication CPT® 2026
HART CADhs®, Atlas Genomics Complete Omics, Inc, Prevencio, Inc	0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD	Revision to Laboratory Name Released to AMA Website December 30, 2024	Revision to Laboratory Name Effective April 1, 2025	Revision to Laboratory Name Publication CPT® 2026
HART CVE®, Atlas Genomics Complete Omics, Inc, Prevencio, Inc	0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	Revision to Laboratory Name Released to AMA Website December 30, 2024	Revision to Laboratory Name Effective April 1, 2025	Revision to Laboratory Name Publication CPT® 2026
HART KD®, Atlas Genomics Complete Omics, Inc, Prevencio, Inc	0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD	Revision to Laboratory Name Released to AMA Website December 30, 2024	Revision to Laboratory Name Effective April 1, 2025	Revision to Laboratory Name Publication CPT® 2026
Helioliver™ Test, Fulgent Genetics, LLC, Helio Health, Inc Helio Genomics®, Helio Genomics®	0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm	Revision to Proprietary and Laboratory Name Released to AMA Website July 1, 2025	Revision to Proprietary and Laboratory Name Effective October 1, 2025	Revision to Proprietary and Laboratory Name Publication CPT® 2026

		reported as normal or abnormal result			
Guardant360 [®] TissueNext [™] , Guardant Health, Inc, Guardant Health, Inc	0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	Revision to Proprietary Name Released to AMA Website July 1, 2025	Revision to Proprietary Name Effective October 1, 2025	Revision to Proprietary Name Publication CPT [®] 2026
QUEST AD-Detect [™] , Beta-Amyloid 42/40 Ratio, Plasma, Quest Diagnostics	0346U	Beta amyloid, A β 40 and A β 42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma	Deletion Released to AMA Website October 1, 2024	Deletion Effective January 1, 2025	Deletion Publication CPT [®] 2026
Neurofilament Light Chain (NFL), Mayo Clinic, Mayo Clinic	0361U	Neurofilament light chain, digital immunoassay, plasma, quantitative	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT [®] 2027
Oncuria [®] Detect, DiaCarta Clinical Lab, DiaCarta, Inc	▲0365U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 ₁ and VEGFA) ₁ by immunoassays, urine, <u>diagnostic algorithm₁ including patient's age, race, and gender,</u> reported as a probability of <u>harboring urothelial-bladder cancer</u>	Revision Released to AMA Website October 1, 2024 Update to Long Descriptor Released to AMA Website July 1, 2025, October 1, 2025	Revision Effective January 1, 2025	Revision Publication CPT [®] 2026
GI assay (Gastrointestinal Pathogen with ABR), Lab Genomics LLC, Thermo Fisher Scientific	0369U	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic resistance genes, multiplex amplified probe technique	Deletion Released to AMA Website April 1, 2025	Deletion Effective July 1, 2025	Deletion Publication CPT [®] 2026
Lesion Infection (Wound), Lab Genomics LLC, Thermo Fisher Scientific	0370U	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34	Deletion Released to AMA Website	Deletion Effective July 1, 2025	Deletion Publication CPT [®] 2026

		microorganisms and identification of 21 associated antibiotic resistance genes, multiplex amplified probe technique, wound swab	April 1, 2025		
Respiratory Pathogen with ABR (RPX), Lab Genomics LLC, Thermo Fisher Scientific	0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen	Deletion Released to AMA Website April 1, 2025	Deletion Effective July 1, 2025	Deletion Publication CPT® 2026
Urogenital Pathogen with Rx Panel (UPX), Lab Genomics LLC, Thermo Fisher Scientific	0374U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic resistance genes, multiplex amplified probe technique, urine	Deletion Released to AMA Website April 1, 2025	Deletion Effective July 1, 2025	Deletion Publication CPT® 2026
PersonalisedRX, Lab Genomics LLC, Agena Bioscience, Inc	0380U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and <i>CYP2D6</i> deletion or duplication analysis with reported genotype and phenotype	Deletion Released to AMA Website October 1, 2024	Deletion Effective January 1, 2025	Deletion Publication CPT® 2026
SAAmplify™-αSYNTap® Biomarker Test, Amprion® Clinical Laboratory, Amprion® Clinical Laboratory	0393U	Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α-synuclein protein by seed amplification assay, qualitative	Revision to Proprietary, Laboratory, and/or Manufacturer Name Released to AMA Website April 1, 2025	Revision to Proprietary, Laboratory, and/or Manufacturer Name Effective July 1, 2025	Revision to Proprietary, Laboratory, and/or Manufacturer Name Publication CPT® 2026
Cxbladder Triage Plus Cxbladder Detect+, Pacific Edge Diagnostics USA LTD, Pacific Edge Diagnostics USA LTD	0420U	Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of <i>MDK</i> , <i>HOXA13</i> , <i>CDC2</i> , <i>IGFBP5</i> , and <i>CXCR2</i> in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) of genes <i>TERT</i> and <i>FGFR3</i> , urine, algorithm reported as a risk score for urothelial carcinoma	Revision to Proprietary Name Released to AMA Website April 1, 2025	Revision to Proprietary Name Effective July 1, 2025	Revision to Proprietary Name Publication CPT® 2026

Epic Sciences ctDNA Metastatic Breast Cancer Panel, Epic Sciences, Inc, Epic Sciences, Inc	●0428U	Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden	September 29, 2023 Deletion Released to AMA Website October 1, 2024	January 1, 2024 Deletion Effective January 1, 2025	CPT® 2025 Deletion Publication CPT® 2026
oncoReveal™ DX Lung and Colon Cancer Assay, Pillar® Biosciences, Pillar® Biosciences	●0448U	Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in <i>EGFR</i> and <i>KRAS</i> genes, formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options	December 28, 2023 Deletion Released to AMA Website October 1, 2024	April 1, 2024 Deletion Effective January 1, 2025	CPT® 2025 Deletion Publication CPT® 2026
M-inSight® Patient Definition Assay, Corgenix Clinical Laboratory, Sebia	0450U	Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides	Deletion Released to AMA Website July 1, 2025	Deletion Effective October 1, 2025	Deletion Publication CPT® 2026
M-inSight® Patient Follow-Up Assessment, Corgenix Clinical Laboratory, Sebia	0451U	Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance	Deletion Released to AMA Website July 1, 2025	Deletion Effective October 1, 2025	Deletion Publication CPT® 2026
PrismRA®, Scipher Medicine®, Scipher Medicine®	●0456U	Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti-cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to	April 1, 2024 Deletion Released to AMA Website October 1, 2024	July 1, 2024 Deletion Effective January 1, 2025	CPT® 2025 Deletion Publication CPT® 2026

		tumor necrosis factor inhibitor (TNFi) therapy			
PrecivityAD2™, C2N Diagnostics, LLC, C2N Diagnostics, LLC	0503U	Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (pTtau217, np-tau217, pTtau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques	Update to Long Descriptor Released to AMA Website July 1, 2025	October 1, 2024	Update to Long Descriptor Publication CPT® 2026
VitaGraft™ Kidney Baseline + 1st Plasma Test, Oncocyte Corporation, Oncocyte Corporation	0508U	Transplantation medicine, quantification of donor-derived cell free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell free DNA with risk for active rejection	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027
VitaGraft™ Kidney Subsequent, Oncocyte Corporation, Oncocyte Corporation	0509U	Transplantation medicine, quantification of donor-derived cell free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell free DNA with risk for active rejection	Deletion Released to AMA Website October 1, 2025	Deletion Effective January 1, 2026	Deletion Publication CPT® 2027
Seronegative Rheumatoid Arthritis Panel, KSL Diagnostics-Beutner Laboratories, Inc, KSL Biomedical, Inc	●0521U	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood	October 1, 2024	January 1, 2025	CPT® 2026
Tissue Specific Markers for Early Diagnosis of Sjögren's Disease, KSL Diagnostics, Inc, KSL Diagnostics, Inc	●0522U	Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiquantitative, blood	October 1, 2024 Revision to Proprietary Name Released to AMA Website April 1, 2025	January 1, 2025	CPT® 2026
oncoReveal™ CDx, Pillar Biosciences, Inc, Pillar Biosciences, Inc	●0523U	Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-	October 1, 2024	January 1, 2025	CPT® 2026

		nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change			
PreClara™ Ratio (sFlt-1/PIGF), Thermo Fisher Scientific, Thermo Fisher Scientific	●0524U	Obstetrics (preeclampsia), sFlt-1/PIGF ratio, immunoassay, utilizing serum or plasma, reported as a value	October 1, 2024 Revision to Proprietary Name Released to AMA Website October 1, 2025	January 1, 2025 Revision to Proprietary Name Effective January 1, 2026	CPT® 2026 Revision Publication CPT® 2027
3D Predict™ Ovarian, Kiyatec®, Inc, Kiyatec®, Inc	●0525U	Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug	October 1, 2024	January 1, 2025	CPT® 2026
CXCL10 Urine Test, One Lambda™, Inc, One Lambda™, Inc	●0526U	Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time	October 1, 2024	January 1, 2025	CPT® 2026
Abbott Alinity™ m HSV 1 & 2 / VZV Assay, Abbott Molecular, Inc	●0527U	Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected	October 1, 2024	January 1, 2025	CPT® 2026
BIOFIRE® FILMARRAY® Pneumonia (PN) Panel, bioMérieux, bioMérieux	●0528U	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria	October 1, 2024	January 1, 2025	CPT® 2026

Lifetime Genomics Risk Assessment, VTE, GenomicMD, Inc, GenomicMD, Inc	●0529U	Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including <i>F2</i> and <i>F5</i> gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE	October 1, 2024	January 1, 2025	CPT® 2026
LiquidHALLMARK®, Lucence Health, Inc, Lucence Health, Inc	●0530U	Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association	October 1, 2024	January 1, 2025	CPT® 2026
NeXGen™ Fungal/AFB NGS Assay, Eurofins Viracor, LLC, Eurofins Viracor, LLC	●0531U	Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma	December 30, 2024	April 1, 2025	CPT® 2026
Rapid Genome Sequencing Test, University of California San Francisco Genomic Medicine Laboratory, University of California San Francisco	●0532U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, peripheral blood, buffy coat, saliva, buccal or tissue sample, results reported as positive or negative	December 30, 2024	April 1, 2025	CPT® 2026
UCSF Pharmacogenomics Panel, University of California San Francisco Genomic Medicine Laboratory, University of California San Francisco	●0533U	Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, <i>ABCG2</i> , <i>CYP2B6</i> , <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2C</i> , <i>CYP2D6</i> , <i>CYP3A5</i> , <i>CYP4F2</i> , <i>DPYD</i> , <i>G6PD</i> , <i>GGCX</i> , <i>NUDT15</i> , <i>SLCO1B1</i> , <i>TPMT</i> , <i>UGT1A1</i> , <i>VKORC1</i>), reported as metabolizer status and transporter function	December 30, 2024	April 1, 2025	CPT® 2026
PROSTOX™ ultra, MiraDx, Inc, MiraDx, Inc	●0534U	Oncology (prostate), microRNA, single-nucleotide polymorphisms (SNPs) analysis by RT-PCR of 32 variants, using buccal swab,	December 30, 2024	April 1, 2025	CPT® 2026

		algorithm reported as a risk score			
PFAS Testing & PFASure®FT, National Medical Services (NMS Labs), Laboratory Developed Test	●0535U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative	December 30, 2024	April 1, 2025	CPT® 2026
Prenatal Detect RhD, Devyser Genomic Laboratories, Devyser AB	●0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of <i>RHD</i> gene and housekeeping control gene <i>GAPDH</i> from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status	December 30, 2024	April 1, 2025	CPT® 2026
Shield™, Guardant Health, Inc, Guardant Health, Inc	●0537U	Oncology (colorectal cancer), analysis of cell-free DNA for epigenomic patterns, next-generation sequencing, >2,500 differentially methylated regions (DMRs), plasma, algorithm reported as positive or negative	December 30, 2024 Update to Long Code Descriptor Released to the AMA Website October 1, 2025	April 1, 2025	CPT® 2026
PredicineATLAS™ Assay, Predicine Inc, Predicine Inc	●0538U	Oncology (solid tumor), next-generation targeted sequencing analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant	December 30, 2024	April 1, 2025	CPT® 2026
PredicineCARE™ Assay, Predicine Inc, Predicine Inc	●0539U	Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152 genes, next-generation sequencing, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, copy	December 30, 2024	April 1, 2025	CPT® 2026

		number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant			
AlloSure®, CareDx® Laboratory, CareDx®, Inc	●0540U	Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection	December 30, 2024	April 1, 2025	CPT® 2026
HDL Reverse Cholesterol Transport Panel with pCAD Score, Quest Diagnostics®, Quest Diagnostics®	●0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score	December 30, 2024	April 1, 2025	CPT® 2026
myOLARIS™-KTdx, Olaris®, Inc, Olaris®, Inc	●0542U	Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of BK virus (human polyomavirus 1) using real-time PCR and serum creatinine, algorithm reported as a probability score for allograft injury status	December 30, 2024	April 1, 2025	CPT® 2026
TruSight™ Oncology Comprehensive, Illumina, Inc	●0543U	Oncology (solid tumor), next-generation sequencing of DNA from formalin-fixed paraffin-embedded (FFPE) tissue of 517 genes, interrogation for single-nucleotide variants, multi-nucleotide variants, insertions and deletions from DNA, fusions in 24 genes and splice variants in 1 gene from RNA, and tumor mutation burden	December 30, 2024	April 1, 2025	CPT® 2026

VitaGraft™ Kidney 2.0, Oncoocyte Corporation, Oncoocyte Corporation	●0544U	Nephrology (transplant monitoring), 48 variants by digital PCR, using cell-free DNA from plasma, donor-derived cell-free DNA, percentage reported as risk for rejection	December 30, 2024 Deletion Released to AMA Website October 1, 2025	April 1, 2025 Deletion Effective January 1, 2026	CPT® 2026 Deletion Publication CPT® 2027
AChR Live Cell-Based Assay, Neurocode USA, Inc, Neurocode USA, Inc	●0545U	Acetylcholine receptor (AChR), antibody identification by immunofluorescence, using live cells, reported as positive or negative	December 30, 2024	April 1, 2025	CPT® 2026
LRP4 Cell-Based Assay, Neurocode USA, Inc, Neurocode USA, Inc	●0546U	Low-density lipoprotein receptor-related protein 4 (LRP4), antibody identification by immunofluorescence, using live cells, reported as positive or negative	December 30, 2024	April 1, 2025	CPT® 2026
Neurofilament Light Blood Test, Neurocode USA, Inc, Fujirebio Diagnostics, Inc	●0547U	Neurofilament light chain (NfL), chemiluminescent enzyme immunoassay, plasma, quantitative	December 30, 2024	April 1, 2025	CPT® 2026
Glial Fibrillary Acidic Protein Blood Test, Neurocode USA, Inc, Fujirebio Diagnostics, Inc	●0548U	Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme immunoassay, using plasma	December 30, 2024	April 1, 2025	CPT® 2026
Bladder CARE™, Pangea Laboratory LLC, Pangea Laboratory LLC	●0549U	Oncology (urothelial), DNA, quantitative methylated real-time PCR of TRNA-Cys, SIM2, and NKX1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC)	December 30, 2024	April 1, 2025	CPT® 2026
ClarityDx Prostate, Protean BioDiagnostics, Protean BioDiagnostics	●0550U	Oncology (prostate), enzyme-linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer	December 30, 2024 Deletion Released to AMA Website October 1, 2025	April 1, 2025 Deletion Effective January 1, 2026	CPT® 2026 Deletion Publication CPT® 2027

LucentAD p-Tau 217, Quanterix Corporation, Quanterix Corporation	●0551U	Tau, phosphorylated, pTau217, by single-molecule array (ultrasensitive digital protein detection), using plasma	December 30, 2024 Deletion Released to AMA Website October 1, 2025	April 1, 2025 Deletion Effective January 1, 2026	CPT® 2026 Deletion Publication CPT® 2027
PGT-M, Igenomix®, Part of Vitrolife Group™, Igenomix®	●0552U	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy, linkage analysis of disease- causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder	April 1, 2025	July 1, 2025	CPT® 2026
Smart PGT-A Plus, Igenomix®, Part of Vitrolife Group™, Thermo Fisher Scientific	●0553U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested	April 1, 2025	July 1, 2025	CPT® 2026
Smart PGT-SR, Igenomix®, Part of Vitrolife Group™, Thermo Fisher Scientific	●0554U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophectoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or	April 1, 2025	July 1, 2025	CPT® 2026

		inconsistent cohort when applicable, per embryo tested			
Smart PGT-SR Plus, Igenomix®, Part of Vitrolife Group™, Thermo Fisher Scientific	●0555U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophoctoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested	April 1, 2025	July 1, 2025	CPT® 2026
HealthTrackRx Bronchitis, HealthTrackRx, Thermo Fisher Scientific	●0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	April 1, 2025	July 1, 2025	CPT® 2026
HealthTrackRx Vaginitis, HealthTrackRx, Thermo Fisher Scientific	●0557U	Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (BVAB-2, BVAB-3), Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei), Herpes simplex viruses 1 and 2, vaginal fluid, reported as	April 1, 2025	July 1, 2025	CPT® 2026

		detected or not detected for each organism			
IGoCheck™ (Blood-Based Colorectal Cancer Test), Milagen, Inc, Milagen, Inc	●0558U	Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression	April 1, 2025	July 1, 2025	CPT® 2026
MammoCheck™ (Blood-Based Breast Cancer Test), Milagen, Inc, Milagen, Inc	●0559U	Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression	April 1, 2025	July 1, 2025	CPT® 2026
Haystack MRD™ Baseline, Quest Diagnostics®, Quest Diagnostics®	●0560U	Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood and tumor tissue, baseline assessment for design and construction of a personalized variant panel to evaluate current MRD and for comparison to subsequent MRD assessments	April 1, 2025	July 1, 2025	CPT® 2026
Haystack MRD™ Monitoring, Quest Diagnostics®, Quest Diagnostics®	●0561U	Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood, subsequent assessment with comparison to initial assessment to evaluate for MRD	April 1, 2025	July 1, 2025	CPT® 2026
PGDx elio™ plasma focus Dx, Personal Genome Diagnostics Inc	●0562U	Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as	April 1, 2025	July 1, 2025	CPT® 2026

		presence of actionable variants			
BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Respiratory Menu, bioMérieux, bioMérieux	●0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative	April 1, 2025	July 1, 2025	CPT® 2026
BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Sore Throat Menu, bioMérieux, bioMérieux	●0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative	April 1, 2025	July 1, 2025	CPT® 2026
EarlyDx MethylScan™ HCC, EarlyDiagnostics Laboratory, EarlyDiagnostics, Inc	●0565U	Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6,626 epigenetic alterations, cell-free DNA, plasma, algorithm reported as cancer signal detected or not detected	April 1, 2025 Update to Long Code Descriptor Released to the AMA Website October 1, 2025	July 1, 2025	CPT® 2026
EPISEEK™ MPE (Malignant Pleural Effusion Detection Test), Precision Epigenomics Inc, Precision Epigenomics Inc	●0566U	Oncology (lung), qPCR-based analysis of 13 differentially methylated regions (<i>CCDC181</i> , <i>HOXA7</i> , <i>LRRC8A</i> , <i>MARCHF11</i> , <i>MIR129-2</i> , <i>NCOR2</i> , <i>PANTR1</i> , <i>PRKCB</i> , <i>SLC9A3</i> , <i>TBR1_2</i> , <i>TRAP1</i> , <i>VWC2</i> , <i>ZNF781</i>), pleural fluid, algorithm reported as a qualitative result	April 1, 2025	July 1, 2025	CPT® 2026
Genomic Unity® 2.0, Variantyx Inc, Variantyx Inc	●0567U	Rare diseases (constitutional/heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number	April 1, 2025	July 1, 2025	CPT® 2026

		variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants			
LucentAD™ Complete, Quanterix Corporation, Quanterix Corporation	●0568U	Neurology (dementia), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio), tau-protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology	April 1, 2025	July 1, 2025	CPT® 2026
Guardant Reveal™, Guardant Health, Inc, Guardant Health, Inc	●0569U	Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20,000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate	April 1, 2025 Update to Long Code Descriptor Released to the AMA Website October 1, 2025	July 1, 2025	CPT® 2026
i-STAT TBI, Abbott Point of Care	●0570U	Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison	April 1, 2025	July 1, 2025	CPT® 2026
LiquidHALLMARK® ctDNA and ctRNA, Lucence	●0571U	Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation	April 1, 2025	July 1, 2025	CPT® 2026

Health, Inc, Lucence Health, Inc		sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants			
ProsTAV®, Life Length S.L., Life Length S.L.	●0572U	Oncology (prostate), high-throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer	April 1, 2025	July 1, 2025	CPT® 2026
Amplified Sciences PanCystPro™, Amplified Sciences, Inc	●0573U	Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastrin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous	April 1, 2025	July 1, 2025	CPT® 2026
NanoDetect-TB™, NanoPin Technologies, Inc	●0574U	Mycobacterium tuberculosis, culture filtrate protein–10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS)	April 1, 2025	July 1, 2025	CPT® 2026
HepatoTrack™, LuminoDx Laboratory, LuminoDx Inc	●0575U	Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (<i>miR-122</i> , <i>miR-885</i> , <i>miR-23a</i> housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection	July 1, 2025	October 1, 2025	CPT® 2026
OmniGraf® Liver, Eurofins Transplant Genomics, LLC, Eurofins Transplant Genomics, LLC	●0576U	Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score	July 1, 2025	October 1, 2025	CPT® 2026
GlycoKnow™ Ovarian, InterVenn Biosciences	●0577U	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode,	July 1, 2025	October 1, 2025	CPT® 2026

		reported as likelihood of malignancy			
Merlin™ Test, SkylineDx USA, Inc, SkylineDx USA, Inc	●0578U	Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence	July 1, 2025	October 1, 2025	CPT® 2026
Promarker®D, Proteomics International USA, Proteomics International Pty Ltd	●0579U	Nephrology (diabetic chronic kidney disease), enzyme-linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline	July 1, 2025	October 1, 2025	CPT® 2026
iDart™ Lyme IgG ImmunoBlot Kit, ID-FISH Technology, Inc	●0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG	July 1, 2025	October 1, 2025	CPT® 2026
Autoantibody to Non-Human Leukocyte Antigen (non-HLA), Mayo Clinic Jacksonville, Mayo Clinic	●0581U	Transplantation medicine, antibody to non-human leukocyte antigens (non-HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported	July 1, 2025	October 1, 2025	CPT® 2026
Rapid Whole Genome Sequencing, Mayo Clinic, Mayo Clinic	●0582U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported	July 1, 2025	October 1, 2025	CPT® 2026
Rapid Genome Sequencing Family Member Comparator, Mayo Clinic, Mayo Clinic	+●0583U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy	July 1, 2025	October 1, 2025	CPT® 2026

		number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure) (Use 0583U in conjunction with 0582U)			
RT-QuIC Prion, CSF, Mayo Clinic, Mayo Clinic	✕●0584U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative (For additional PLA code with identical clinical descriptor, see 0035U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)	July 1, 2025	October 1, 2025	CPT® 2026
Labcorp® Plasma Complete™, Labcorp, Laboratory Developed Test	●0585U	Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability	July 1, 2025	October 1, 2025	CPT® 2026
RNA Salah Targeted Expression Panel, Moffitt Cancer Center Advanced Diagnostics Laboratory, Laboratory Developed Test	●0586U	Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin-fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene	July 1, 2025	October 1, 2025	CPT® 2026
SafeDrugs, Astraerus Lab, LLC, Quantllo Technologies	●0587U	Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score	July 1, 2025	October 1, 2025	CPT® 2026

		predicted for adverse drug effects			
TriVerity™, Inflammatrix™, Inc	●0588U	Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RT-LAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days	July 1, 2025	October 1, 2025	CPT® 2026
PFAS (Forever Chemicals) Panel 2 – 24 PFAS, Quest Diagnostics®, Quest Diagnostics®	●0589U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative	July 1, 2025	October 1, 2025	CPT® 2026
BIOTIA-ID™ Urine NGS Assay, Biotia Inc, Biotia Inc	●0590U	Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism	July 1, 2025	October 1, 2025	CPT® 2026
MiCheck® Prostate, Minomic®, Inc, Minomic®, Inc	●0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer	July 1, 2025	October 1, 2025	CPT® 2026
Aventa Lymphoma, Aventa Genomics, LLC	●0592U	Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor	July 1, 2025	October 1, 2025	CPT® 2026

		tissue, results report clinically significant variant(s)			
Taq Array Card Urinary Tract Infection PCR Panel, SoftCell Laboratories LLC, Doc Lab Inc	●0593U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected	July 1, 2025	October 1, 2025	CPT® 2026
IVD CAPSULE PSP – Rapid Sepsis Test, Abionic SA	●0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis	July 1, 2025	October 1, 2025	CPT® 2026
BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel, bioMérieux, bioMérieux	●0595U	Infectious disease (tropical fever pathogens), vector-borne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RT-PCR, whole blood, each pathogen reported as detected or not detected	July 1, 2025	October 1, 2025	CPT® 2026
Precivity-ApoE™, C2N Diagnostics, LLC	●0596U	Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LC-MS/MS), reported as an APOE prototype <u>proteotype</u>	July 1, 2025 Update to Long Code Descriptor Released to the AMA Website October 1, 2025	October 1, 2025	CPT® 2026 Update to Long Code Descriptor Publication CPT® 2027
AidaBreast™, PreludeDx™, Prelude Corporation	●0597U	Oncology (breast), RNA expression profiling of 329 genes by targeted next-generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic analyses to	July 1, 2025	October 1, 2025	CPT® 2026

		determine tumor-recurrence risk score			
inFoods® IBS, Ethos Laboratories, Biomerica	●0598U	Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels	July 1, 2025	October 1, 2025	CPT® 2026
PancreaSure™, Immunovia, Inc, Immunovia, Inc	●0599U	Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative	July 1, 2025	October 1, 2025	CPT® 2026
FidaLab Molecular Wound Infection Test, FidaLab LLC, FidaLab LLC	●0600U	Infectious disease (wound infection), identification of 65 organisms and 30 antibiotic resistance genes, wound swab, real-time PCR, reported as positive or negative for each organism	October 1, 2025	January 1, 2026	CPT® 2027
Synovasure® Comprehensive PJI Test Panel with SynTuition™, CD Laboratories, Inc, a division of Zimmer Biomet, CD Diagnostics, Inc, a division of Zimmer Biomet	●0601U	Infectious disease (periprosthetic joint infection), analysis of 11 biomarkers (alpha defensins 1–3, C-reactive protein, microbial antigens for Staphylococcus [SPA, SPB], Enterococcus, Candida, and C. acnes, total nucleated cell count, percent neutrophils, RBC count, and absorbance at 280 nm) using immunoassays, hematology, clinical chemistry, synovial fluid, and diagnostic algorithm reported as a probability score	October 1, 2025	January 1, 2026	CPT® 2027
Kihealth Inc® Diabetes Risk Test, Kihealth Inc® Laboratory	●0602U	Endocrinology (diabetes), insulin (<i>INS</i>) gene methylation using digital droplet PCR, insulin, and C-peptide immunoassay, serum, Hemoglobin A1c immunoassay, whole blood, algorithm reported as diabetes-risk score	October 1, 2025	January 1, 2026	CPT® 2027
SLL Comprehensive Drug Analysis, Soft Landing Labs, Soft Landing Labs	●0603U	Drug assay, presumptive, 77 drugs or metabolites, urine, liquid chromatography with	October 1, 2025	January 1, 2026	CPT® 2027

		tandem mass spectrometry (LC-MS/MS), results reported as positive or negative			
Bradykinin, Quantitative, by LC-MS/MS, Virant Diagnostics, Inc	●0604U	Allergy and immunology (chronic recurrent angioedema), 4 bradykinin peptides, liquid chromatography and tandem mass spectrometry (LC-MS/MS), whole blood, quantitative	October 1, 2025	January 1, 2026	CPT® 2027
Tryptase Gene Copy Number Analysis by dPCR, Virant Diagnostics, Inc	●0605U	Allergy and immunology (hereditary alpha tryptasemia), DNA, analysis of <i>TPSAB1</i> gene copy number variation using digital PCR, whole blood, results reported with genotype-specific interpretation of alpha-tryptase copy number and algorithmic classification as normal or abnormal	October 1, 2025	January 1, 2026	CPT® 2027
Osmotic Gradient Ektacytometry, Cincinnati Children's Clinical Laboratories, RR Mechatronics	●0606U	Hematology (red cell membrane disorders), RBCs, osmotic gradient ektacytometry, whole blood, quantitative	October 1, 2025	January 1, 2026	CPT® 2027
EMMA (Endometrial Microbiome Metagenomic Analysis), Igenomix®, Igenomix® USA	●0607U	Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 31 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations	October 1, 2025	January 1, 2026	CPT® 2027
ALICE (Analysis of Infectious Chronic Endometritis), Igenomix®, Igenomix® USA	●0608U	Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 10 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations (Do not report 0608U in conjunction with 0607U)	October 1, 2025	January 1, 2026	CPT® 2027
ClarityDX Prostate, Protean BioDiagnostics, Nanostics Inc	●0609U	Oncology (prostate), immunoassay for total prostate-specific antigen (PSA) and free PSA, serum or plasma, combined with	October 1, 2025	January 1, 2026	CPT® 2027

		clinical features, algorithm reported as a probability score for clinically significant prostate cancer			
LifeScale Gram Negative Kit (LSGN) with the LifeScale AST system, Affinity Biosensors, LLC, Affinity Biosensors, LLC	●0610U	Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial susceptibility testing of positive blood culture using microfluidic sensor technology to quantify bacterial growth response to multiple antibiotic types, reporting categorical susceptibility (susceptible, susceptible dose dependent, intermediate, resistant), minimum inhibitory concentration, and interpretive comments	October 1, 2025	January 1, 2026	CPT® 2027
HelioHCC™ Strat, Helio Genomics®, Helio Genomics®	✕●0611U	Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result (For additional PLA code with identical clinical descriptor, see 0612U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)	October 1, 2025	January 1, 2026	CPT® 2027
HelioHCC™ Trace, Helio Genomics®, Helio Genomics®	✕●0612U	Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result (For additional PLA code with identical clinical descriptor, see 0611U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)	October 1, 2025	January 1, 2026	CPT® 2027
AssureMDx™, Vesica Health® Inc	●0613U	Oncology (urothelial carcinoma), DNA methylation and mutation analysis of 6 biomarkers (TWIST1, OTX1, ONECUT2, FGFR3, HRAS, TERT promoter region), methylation-specific PCR and	October 1, 2025	January 1, 2026	CPT® 2027

		targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma			
--	--	---	--	--	--